Grace Therapeutics (GRCE) Other Non-Current Liabilities (2019 - 2025)

Grace Therapeutics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $201000.0 in Q3 2025.

• Quarterly Other Non-Current Liabilities fell 92.28% year-over-year to $201000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $201000.0 (down 92.28% YoY) and the FY2025 annual result came in at $1.1 million, down 73.82% from the prior year.
• Other Non-Current Liabilities eased to $201000.0 in Q3 2025 per GRCE's latest filing, from $1.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.2 million in Q1 2021 and troughed at $10000.0 in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Other Non-Current Liabilities soared 118.09% in 2021, then slumped 99.81% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $268000.0 in 2021, then sank by 96.27% to $10000.0 in 2022, then soared by 33220.0% to $3.3 million in 2023, then rose by 13.48% to $3.8 million in 2024, then slumped by 94.68% to $201000.0 in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $201000.0, $1.6 million, and $1.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.